# Potentia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/potentia

- Industry: Biotechnology
- Headquarters: Tel Aviv, Israel
- Total disclosed funding: $0.9M
- Latest round: Seed (May 5, 2026)
- Investors on record: 1

## About

Based in Israel, and founded in 2022, Potentia Therapeutics is a biotechnology company pioneering a breakthrough Antibody-Oligonucleotide Conjugate (AOC) platform specifically engineered to treat diseases of the Peripheral Nervous System. Based in Israel, and founded in 2022, Potentia Therapeutics is a biotechnology company pioneering a breakthrough Antibody-Oligonucleotide Conjugate (AOC) platform specifically engineered to treat diseases of the Peripheral Nervous System. In May 2026, Potentia Ltd. raised USD 0.90 million in seed funding from Peregrine Ventures. Potentia Therapeutics develops biotechnology products for patients affected by Peripheral Nervous System disorders. Its core technology is an Antibody-Oligonucleotide Conjugate (AOC) platform that combines immunology-based targeting with short interfering RNA (siRNA) gene-silencing technology. The company’s lead program is directed toward Charcot-Marie-Tooth disease 1A (CMT1A), with the objective of restoring myelin formation and nerve function.

## Funding rounds

- Seed, May 5, 2026, $0.9M — Peregrine Ventures

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Seed